GSK to Announce Q4 Earnings on February 4
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Should l Buy GSK?
Source: seekingalpha
- Earnings Announcement: GSK is set to release its Q4 2023 earnings on February 4 before market open, with consensus EPS estimate at $0.62, reflecting a 97.3% year-over-year decline, while revenue is projected at $11.57 billion, indicating a robust 42.7% year-over-year growth.
- Historical Performance: Over the past two years, GSK has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, demonstrating the company's financial stability and bolstering market confidence.
- Estimate Revisions: In the last three months, GSK's EPS estimates have seen two upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and two downward adjustments, indicating analysts' optimistic outlook on the company's future performance.
- Market Attention: The earnings release coincides with reports from major companies such as Amazon, Google, and Pfizer, which could influence overall market sentiment and investor decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 52.470
Low
20.15
Averages
38.72
High
55.60
Current: 52.470
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GSK to Announce Q4 Earnings on February 4
- Earnings Announcement: GSK is set to release its Q4 2023 earnings on February 4 before market open, with consensus EPS estimate at $0.62, reflecting a 97.3% year-over-year decline, while revenue is projected at $11.57 billion, indicating a robust 42.7% year-over-year growth.
- Historical Performance: Over the past two years, GSK has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, demonstrating the company's financial stability and bolstering market confidence.
- Estimate Revisions: In the last three months, GSK's EPS estimates have seen two upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and two downward adjustments, indicating analysts' optimistic outlook on the company's future performance.
- Market Attention: The earnings release coincides with reports from major companies such as Amazon, Google, and Pfizer, which could influence overall market sentiment and investor decisions.
See More
Wave Life Sciences Regains Full Rights to WVE-006 from GSK
- Rights Reinstatement: Wave Life Sciences Ltd. announced it regained full rights to WVE-006 from GSK Plc, indicating the company's strategic capability to advance its program for the rare disease alpha-1 antitrypsin deficiency (AATD), which is expected to accelerate development efforts.
- Clinical Trial Progress: Data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial is anticipated in the first quarter of 2026, with single-dose and 600 mg final cohort data also expected in the same year, providing critical evidence for subsequent registration applications.
- Regulatory Strategy: Wave is accelerating its registrational strategy for WVE-006 and plans to engage with the U.S. Food and Drug Administration (FDA) for a potential accelerated approval pathway, with regulatory feedback expected by mid-2026, which will positively impact the company's future market access.
- Collaboration Outlook: Under its collaboration with GSK, Wave has the opportunity to earn up to $2.8 billion in milestone payments, with GSK selecting a fourth program for development, showcasing the ongoing collaborative potential across multiple therapeutic areas.
See More
Wave Life Sciences Regains AATD Asset WVE-006 from GSK
- Asset Recovery: Wave Life Sciences has regained the alpha-1 antitrypsin deficiency (AATD) asset WVE-006 from GSK, indicating the company's capability to efficiently advance the program, with plans to accelerate registration for seeking expedited approval.
- FDA Engagement: The company plans to engage with the US FDA regarding a potential accelerated approval filing, with feedback expected mid-year, which will provide crucial guidance for subsequent clinical trials and market launch.
- Clinical Data Release: Wave noted that data from the multidose cohort of the RestorAATion-2 clinical trial is on schedule for release in Q1, which will provide critical evidence for the efficacy of WVE-006 and further bolster market confidence.
- Market Gap: WVE-006 is considered a GalNAc-conjugated RNA editing oligonucleotide, and there are currently no approved therapies that address both lung and liver impacts of the disease, highlighting the product's market potential and strategic significance.
See More
Super Bowl of Earnings for S&P 500
- Disney Earnings Highlights: Disney reported Q1 EPS of $1.63, surpassing the $1.57 estimate, with revenue of $25.98 billion exceeding expectations of $25.74 billion, indicating strong performance in the entertainment sector, although CEO Bob Iger plans to step back from daily management before his contract ends.
- Palantir Earnings Focus: Palantir is set to report earnings after Monday's close, with investors closely monitoring its commercial customer count and average revenue per customer, as these metrics reflect the adoption of its AI platforms beyond government contracts, impacting its high valuation sustainability.
- AMD Earnings Expectations: Analysts expect AMD to report earnings of $1.32 per share on revenue of $9.67 billion, with the market anticipating a beat-and-raise quarter driven by growth in MI350 AI accelerators and server CPU market share gains, potentially pushing the stock to new all-time highs.
- Google Cloud Competitiveness: Investors will keep an eye on Google Cloud's momentum and the successful monetization of Gemini AI within search and YouTube to ensure the company maintains its competitive edge against AI rivals, especially in light of its massive capital expenditure plans for AI infrastructure.
See More
Key Highlights to Monitor This Week: Jobs Report, Amazon, Disney, Alphabet, Palantir, and More
Market Volatility: Last week saw increased volatility in equities, with the S&P 500 ending slightly up and the Nasdaq Composite slightly down after a steady interest rate announcement by the Federal Open Market Committee.
Microsoft's Earnings Impact: Microsoft experienced a significant drop of 10% in its stock value, resulting in a loss of $357 billion in market capitalization following a disappointing earnings report.
Silver Market Collapse: The silver market faced a dramatic decline, falling 31% in a single day, attributed to the nomination of hawkish Kevin Warsh as the next Fed Chair and a prior 50% increase in value this year.
Overall Economic Sentiment: The combination of these events reflects a turbulent economic sentiment, with investors reacting to both corporate earnings and shifts in monetary policy.
See More
Trump Administration Launches Medicare Drug Price Negotiations
- Expansion of Drug Negotiations: The Trump administration has expanded Medicare drug price negotiations to include treatments administered in doctors' offices for conditions such as diabetes and HIV, affecting 15 drugs set to take effect in 2028, aiming to reduce out-of-pocket costs for beneficiaries.
- Spending Overview: According to the Centers for Medicare and Medicaid Services, approximately 1.8 million beneficiaries utilized these medications between 2024 and 2025, accounting for about $27 billion in spending, highlighting the significance of Medicare expenditures in drug price negotiations.
- Pharmaceutical Impact Assessment: Analysts indicate that for 14 of the drugs, only Gilead's Biktarvy significantly impacts the company's estimated 2027 global sales, representing around 8%, while other drugs' Medicare revenue exposure is limited to 0% to 3%, suggesting minimal overall revenue impact for pharmaceutical companies.
- Kaiser Settlement on Fraud: Kaiser Permanente has agreed to a historic $556 million settlement over Medicare Advantage fraud allegations, reflecting the government's stringent enforcement stance on Medicare fraud, which could have far-reaching implications for the industry.
See More
GSK to Announce Q4 Earnings on February 4
- Earnings Announcement: GSK is set to release its Q4 2023 earnings on February 4 before market open, with consensus EPS estimate at $0.62, reflecting a 97.3% year-over-year decline, while revenue is projected at $11.57 billion, indicating a robust 42.7% year-over-year growth.
- Historical Performance: Over the past two years, GSK has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, demonstrating the company's financial stability and bolstering market confidence.
- Estimate Revisions: In the last three months, GSK's EPS estimates have seen two upward revisions and no downward adjustments, while revenue estimates experienced four upward revisions and two downward adjustments, indicating analysts' optimistic outlook on the company's future performance.
- Market Attention: The earnings release coincides with reports from major companies such as Amazon, Google, and Pfizer, which could influence overall market sentiment and investor decisions.
See More
Wave Life Sciences Regains Full Rights to WVE-006 from GSK
- Rights Reinstatement: Wave Life Sciences Ltd. announced it regained full rights to WVE-006 from GSK Plc, indicating the company's strategic capability to advance its program for the rare disease alpha-1 antitrypsin deficiency (AATD), which is expected to accelerate development efforts.
- Clinical Trial Progress: Data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial is anticipated in the first quarter of 2026, with single-dose and 600 mg final cohort data also expected in the same year, providing critical evidence for subsequent registration applications.
- Regulatory Strategy: Wave is accelerating its registrational strategy for WVE-006 and plans to engage with the U.S. Food and Drug Administration (FDA) for a potential accelerated approval pathway, with regulatory feedback expected by mid-2026, which will positively impact the company's future market access.
- Collaboration Outlook: Under its collaboration with GSK, Wave has the opportunity to earn up to $2.8 billion in milestone payments, with GSK selecting a fourth program for development, showcasing the ongoing collaborative potential across multiple therapeutic areas.
See More
Wave Life Sciences Regains AATD Asset WVE-006 from GSK
- Asset Recovery: Wave Life Sciences has regained the alpha-1 antitrypsin deficiency (AATD) asset WVE-006 from GSK, indicating the company's capability to efficiently advance the program, with plans to accelerate registration for seeking expedited approval.
- FDA Engagement: The company plans to engage with the US FDA regarding a potential accelerated approval filing, with feedback expected mid-year, which will provide crucial guidance for subsequent clinical trials and market launch.
- Clinical Data Release: Wave noted that data from the multidose cohort of the RestorAATion-2 clinical trial is on schedule for release in Q1, which will provide critical evidence for the efficacy of WVE-006 and further bolster market confidence.
- Market Gap: WVE-006 is considered a GalNAc-conjugated RNA editing oligonucleotide, and there are currently no approved therapies that address both lung and liver impacts of the disease, highlighting the product's market potential and strategic significance.
See More
Super Bowl of Earnings for S&P 500
- Disney Earnings Highlights: Disney reported Q1 EPS of $1.63, surpassing the $1.57 estimate, with revenue of $25.98 billion exceeding expectations of $25.74 billion, indicating strong performance in the entertainment sector, although CEO Bob Iger plans to step back from daily management before his contract ends.
- Palantir Earnings Focus: Palantir is set to report earnings after Monday's close, with investors closely monitoring its commercial customer count and average revenue per customer, as these metrics reflect the adoption of its AI platforms beyond government contracts, impacting its high valuation sustainability.
- AMD Earnings Expectations: Analysts expect AMD to report earnings of $1.32 per share on revenue of $9.67 billion, with the market anticipating a beat-and-raise quarter driven by growth in MI350 AI accelerators and server CPU market share gains, potentially pushing the stock to new all-time highs.
- Google Cloud Competitiveness: Investors will keep an eye on Google Cloud's momentum and the successful monetization of Gemini AI within search and YouTube to ensure the company maintains its competitive edge against AI rivals, especially in light of its massive capital expenditure plans for AI infrastructure.
See More
Key Highlights to Monitor This Week: Jobs Report, Amazon, Disney, Alphabet, Palantir, and More
Market Volatility: Last week saw increased volatility in equities, with the S&P 500 ending slightly up and the Nasdaq Composite slightly down after a steady interest rate announcement by the Federal Open Market Committee.
Microsoft's Earnings Impact: Microsoft experienced a significant drop of 10% in its stock value, resulting in a loss of $357 billion in market capitalization following a disappointing earnings report.
Silver Market Collapse: The silver market faced a dramatic decline, falling 31% in a single day, attributed to the nomination of hawkish Kevin Warsh as the next Fed Chair and a prior 50% increase in value this year.
Overall Economic Sentiment: The combination of these events reflects a turbulent economic sentiment, with investors reacting to both corporate earnings and shifts in monetary policy.
See More
Trump Administration Launches Medicare Drug Price Negotiations
- Expansion of Drug Negotiations: The Trump administration has expanded Medicare drug price negotiations to include treatments administered in doctors' offices for conditions such as diabetes and HIV, affecting 15 drugs set to take effect in 2028, aiming to reduce out-of-pocket costs for beneficiaries.
- Spending Overview: According to the Centers for Medicare and Medicaid Services, approximately 1.8 million beneficiaries utilized these medications between 2024 and 2025, accounting for about $27 billion in spending, highlighting the significance of Medicare expenditures in drug price negotiations.
- Pharmaceutical Impact Assessment: Analysts indicate that for 14 of the drugs, only Gilead's Biktarvy significantly impacts the company's estimated 2027 global sales, representing around 8%, while other drugs' Medicare revenue exposure is limited to 0% to 3%, suggesting minimal overall revenue impact for pharmaceutical companies.
- Kaiser Settlement on Fraud: Kaiser Permanente has agreed to a historic $556 million settlement over Medicare Advantage fraud allegations, reflecting the government's stringent enforcement stance on Medicare fraud, which could have far-reaching implications for the industry.
See More
